Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35727695.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1213 and PMC identifier 9614185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The novel combination of checkpoint inhibitors targeting the PD(L)1 pathway and anti-VEGFA therapy has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, biomarkers predictive of response to these therapies are still lacking, representing a major clinical challenge. See related articles by Zhang et al., p. 3499, and Zhu et al., p. 3537.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms